search
Back to results

Evaluation of Krio in Children and Adults With Epilepsy (Krio)

Primary Purpose

Ketogenic Dieting, Epilepsy, Glucose Transporter Type 1 Deficiency Syndrome

Status
Withdrawn
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Krio
Sponsored by
Vitaflo International, Ltd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Ketogenic Dieting focused on measuring Ketogenic, Diet, Epilepsy, Glut-1 DS, Krio

Eligibility Criteria

3 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

i) Confirmed diagnosis of a condition requiring a KD, e.g. intractable epilepsy, Glut-1 DS.

ii) Aged three (3) years and over.

iii) Currently established on a KD for at least three (3) months, taken orally.

iv) Participant (or parent/guardian) considered by PI and dietitian to be fully proficient at managing the KD, and able to do this competently and accurately.

v) Participant (or parent/guardian) considered by PI and dietitian to be able to follow the protocol requirements and complete the diary and questionnaire.

vi) Freely given, written, informed consent from patient or parent/guardian.

vii) Freely given, written assent (if appropriate).

Exclusion Criteria:

i) Inability to comply with the study protocol, in the opinion of the investigator.

ii) Inability to comply with the ketogenic diet.

iii) Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period.

N.B.: Women who become pregnant unexpectedly during this study may, in consultation with their doctor, continue on the study's dietary product if they wish but will not have any investigations that would not normally be carried out during pregnancy.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Consumption of Krio

    Arm Description

    Incorporation of Krio into the daily diet.

    Outcomes

    Primary Outcome Measures

    Product compliance daily diary
    Quantitative assessments from subject questionnaires that allow evaluation of compliance with the study product, i.e. actual versus prescribed intake.
    GI tolerance daily diary
    Qualitative assessments from subject questionnaires that allow evaluation of the gastro-intestinal tolerance of the study product.
    Ease of use questionnaire
    Qualitative assessment from subject questionnaire that allows evaluation of the ease of use of the study product.

    Secondary Outcome Measures

    Full Information

    First Posted
    June 26, 2017
    Last Updated
    November 6, 2020
    Sponsor
    Vitaflo International, Ltd
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03202108
    Brief Title
    Evaluation of Krio in Children and Adults With Epilepsy
    Acronym
    Krio
    Official Title
    A Feasibility Study to Evaluate the Acceptability of Krio, a Food for Special Medical Purposes (FSMP) for Use in the Ketogenic Diet (KD) With Regard to Product Tolerance, Compliance and Acceptability
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    November 2020
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Product manufacturing issues.
    Study Start Date
    May 11, 2018 (Actual)
    Primary Completion Date
    June 15, 2018 (Actual)
    Study Completion Date
    June 28, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Vitaflo International, Ltd

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Acceptability study to evaluate the gastrointestinal tolerance, palatability and participant compliance, over a 7-day period, of Krio for the dietary management of participants with intractable epilepsy or Glut-1 deficiency syndrome patients on a ketogenic diet.
    Detailed Description
    This is a prospective, acceptability study in fifteen (15) participants aged three (3) years and over, who are established on a ketogenic diet (KD), of Krio to aid in the management of their diet. Participants will be provided with a 7-day supply of Krio and will be asked to complete a daily diary and short questionnaire to record information allowing assessment the following: Gastrointestinal tolerance Palatability Compliance Krio is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD: classical, medium chain triglyceride (MCT), modified Atkins diet (MAD) and low glycaemic index (LGI). It is suitable from 3 years of age. Krio is presented as a ready to eat solid bar (28g), with no additional preparation required. It contains fat (20g per bar), protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. The recommended intake of the product for each participant will be determined by a dietitian. The quantity to be consumed daily will be recommended on an individual patient basis, but will be a minimum of 1 bar. Product acceptability data from 15 participants are required in order to submit an application to the Advisory Committee on Borderline Substances (ACBS) for product registration.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Ketogenic Dieting, Epilepsy, Glucose Transporter Type 1 Deficiency Syndrome
    Keywords
    Ketogenic, Diet, Epilepsy, Glut-1 DS, Krio

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Consumption of Krio
    Arm Type
    Experimental
    Arm Description
    Incorporation of Krio into the daily diet.
    Intervention Type
    Dietary Supplement
    Intervention Name(s)
    Krio
    Intervention Description
    Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition. It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet. This product is to be consumed daily under the direction of a dietitian.
    Primary Outcome Measure Information:
    Title
    Product compliance daily diary
    Description
    Quantitative assessments from subject questionnaires that allow evaluation of compliance with the study product, i.e. actual versus prescribed intake.
    Time Frame
    Days 1-7
    Title
    GI tolerance daily diary
    Description
    Qualitative assessments from subject questionnaires that allow evaluation of the gastro-intestinal tolerance of the study product.
    Time Frame
    Days 1-7
    Title
    Ease of use questionnaire
    Description
    Qualitative assessment from subject questionnaire that allows evaluation of the ease of use of the study product.
    Time Frame
    Day 8

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    3 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: i) Confirmed diagnosis of a condition requiring a KD, e.g. intractable epilepsy, Glut-1 DS. ii) Aged three (3) years and over. iii) Currently established on a KD for at least three (3) months, taken orally. iv) Participant (or parent/guardian) considered by PI and dietitian to be fully proficient at managing the KD, and able to do this competently and accurately. v) Participant (or parent/guardian) considered by PI and dietitian to be able to follow the protocol requirements and complete the diary and questionnaire. vi) Freely given, written, informed consent from patient or parent/guardian. vii) Freely given, written assent (if appropriate). Exclusion Criteria: i) Inability to comply with the study protocol, in the opinion of the investigator. ii) Inability to comply with the ketogenic diet. iii) Women who are pregnant / breastfeeding at the start of the study or planning to become pregnant during the study period. N.B.: Women who become pregnant unexpectedly during this study may, in consultation with their doctor, continue on the study's dietary product if they wish but will not have any investigations that would not normally be carried out during pregnancy.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Rachel Meskell
    Organizational Affiliation
    Leeds Teaching Hospitals NHS Trust
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided

    Learn more about this trial

    Evaluation of Krio in Children and Adults With Epilepsy

    We'll reach out to this number within 24 hrs